CD274 and neoplasm: The answer lies in combination regimens that modify the tumor microenvironment to potentiate the immunotherapy drug as recently demonstrated by the IMbrave150 trial that combined an anti-PD-L1 antibody with an anti-angiogenesis antibody [15].